Currently, there are 34.94M common shares owned by the public and among those 28.01M shares have been available to trade.
The company’s stock has a 5-day price change of 11.78% and -45.20% over the past three months. MBIO shares are trading -58.59% year to date (YTD), with the 12-month market performance down to -91.00% lower. It has a 12-month low price of $0.13 and touched a high of $6.18 over the same period. MBIO has an average intraday trading volume of 28.55 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 55.38%, 79.44%, and -51.37% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Mustang Bio Inc (NASDAQ: MBIO) shares accounts for 2.54% of the company’s 34.94M shares outstanding.
It has a market capitalization of $19.53M and a beta (3y monthly) value of 1.89. The earnings-per-share (ttm) stands at -$4.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 18.17% over the week and 32.88% over the month.
Earnings per share for the fiscal year are expected to increase by 89.83%, and 42.62% over the next financial year.
Looking at the support for the MBIO, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on May 18, 2021, with the firm’s price target at $11. B. Riley FBR coverage for the Mustang Bio Inc (MBIO) stock in a research note released on October 02, 2020 offered a Buy rating with a price target of $9. Cantor Fitzgerald was of a view on November 20, 2019 that the stock is Overweight, while H.C. Wainwright gave the stock Buy rating on August 13, 2019, issuing a price target of $7. Cantor Fitzgerald on their part issued Overweight rating on June 21, 2019.
